TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-16

Archived explainer. For the current picture see today's AAPG page.

Why Is ASCENTAGE PHARMA GRO ADR (AAPG) Stock Down Today?

By the Top Tier Newswire AI Desk · November 16, 2026 at 9:46 AM ET · reviewed against 3 wire stories

ASCENTAGE PHARMA GRO ADR (AAPG) is down -6.70% in the latest session. Our newswire has captured 3 stories on AAPG across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Ascentage Pharma Group International (AAPG) shares fell 6.70% to $13.64 on Monday, following the announcement that the company’s drug lisaftoclax was added to China’s 2026 National Reimbursement Drug List. The stock also saw the successful renewal of coverage for olverembatinib, with both changes effective January 1, 2027.

What Happened

Ascentage Pharma announced that lisaftoclax was included in China’s 2026 National Reimbursement Drug List for the first time. The company also confirmed the successful renewal of coverage for olverembatinib in the same list. These regulatory updates expand market access for the company’s key products in China, its primary market. The news was reported across multiple financial outlets within the last 36 hours, highlighting the strategic importance of these listings for the company’s commercial pipeline.

What The Data Shows

The stock opened at $14.00, a 4.2% gap down from the prior close of $14.62. The session high was $14.00 at 7:00 AM ET, while the session low reached $13.60 at 9:30 AM ET. Volume so far is 0.0M shares, which is 0.5x the 3-month daily average. Fundamentals show a market cap of $1.3B with the company remaining unprofitable, posting a trailing twelve-month EPS of -0.58. Revenue grew 64.5% over the trailing twelve months, but the net margin stands at -228.5%. The stock has a beta of 0.77 and a 52-week range of $13.46 to $34.50. Over the last 8 sessions, the stock moved -3.0% from $15.07 to $14.62. The 52-week tape recorded one fresh 52-week high and one fresh 52-week low on November 16, 2026.

What To Watch

Ascentage Pharma is scheduled to present clinical and preclinical data at the 68th ASH Annual Meeting. The company will present data on four innovative drug candidates, including first clinical results for APG-5918. Additionally, the company is set to participate in two upcoming investor conferences in London.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

AAPG by the numbers

Last: $13.64Session: -6.70%7 sessions: -12.16%Coverage: 3 stories / 3 sourcesAI sentiment: 64/100 (bullish)Mkt cap: $1.3B52w: $13.46 to $34.50
AAPG · Nov 16 session (5-min) · -9.10% vs prior close · updated 8:58 PM ET
$13.21$13.95$14.70prev close $14.62$13.297:00 AM9:13 AM11:27 AM1:41 PM3:55 PM7:00 AM · $14.009:30 AM · $13.609:35 AM · $13.899:40 AM · $13.649:45 AM · $13.649:50 AM · $13.6410:40 AM · $13.6411:45 AM · $13.5612:00 PM · $13.6312:05 PM · $13.5912:10 PM · $13.5612:20 PM · $13.581:30 PM · $13.502:15 PM · $13.432:40 PM · $13.433:30 PM · $13.433:45 PM · $13.303:50 PM · $13.303:55 PM · $13.29
AI sentiment, last 36h · averaged over 3 stories · 64/100 bullish
AI sentiment 64/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishBusiness Insider · sentiment 64 · Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for OlverembatinibBusiness Insider · 64Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursemen…The Fly · sentiment 64 · Ascentage Pharma announces inclusion of Lisaftoclax in China’s NRDL 2026The Fly · 64Ascentage Pharma announces inclusion of Lisaftoclax in China’s NRDL 2026GuruFocus · sentiment 64 · Ascentage Pharma (AAPG) Secures Key Drug Listings in China's 2026 NRDL, Expanding Market AccessGuruFocus · 64Ascentage Pharma (AAPG) Secures Key Drug Listings in China's 2026 NRDL, Expanding Market …
4d agoGuruFocusBULLISH 64Product/PR

Ascentage Pharma (AAPG) Secures Key Drug Listings in China's 2026 NRDL, Expanding Market Access

4d agoThe FlyBULLISH 64Product/PR

Ascentage Pharma announces inclusion of Lisaftoclax in China’s NRDL 2026

4d agoBusiness InsiderBULLISH 64Product/PR

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the...

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on AAPG: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier AAPG move explainers: 2026-11-16